Short answer
Stryker Corporation (SYK) filed an 8-K current report with the SEC on April 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 operating results announced April 30, 2026.
Stryker Corporation 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 operating results announced April 30, 2026
- Exhibit 99.1 contains the detailed earnings release and financial figures
- Results furnished under Item 2.02, limiting Section 18 liability and automatic incorporation into other filings
Item EX-99.1 · Exhibit EX-99.1
- Q1 2026 sales $6.02B, up 2.6%; organic growth 2.4%, supported by 2.1% unit volume and 0.3% pricing
- Adjusted EPS $2.60, down 8.5%; adjusted operating margin contracted 180 bps to 21.1%, signaling significant profitability pressure
- MedSurg and Neurotechnology organic growth 0.9% versus Orthopaedics 4.1%, with Vascular up 27.5% and Trauma and Extremities up 9.5%
- Operating cash flow improved to $581M from $250M; debt payments totaled $1.0B, reducing cash to $2.878B
- Full-year guidance maintained: organic sales growth 8.0%-9.5% and adjusted EPS $14.90-$15.10
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Stryker Corporation 8-K filings
Get the next SYK 8-K as it lands
Follow SYK for push alerts, or ask the research agent what this filing means.